Invex Therapeutics Ltd (ASX: IXC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Invex Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Invex Therapeutics Ltd (ASX: IXC)
Latest News
Share Gainers
This ASX healthcare company just got FDA approval, and its share price is soaring 18%
IXC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Invex Therapeutics Ltd
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
IXC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
29 Oct 2024 | $0.09 | $0.00 | 0.00% | 10,000 | $0.09 | $0.09 | $0.09 |
28 Oct 2024 | $0.09 | $0.01 | 12.99% | 134,897 | $0.09 | $0.09 | $0.09 |
25 Oct 2024 | $0.08 | $-0.01 | -12.20% | 6,642 | $0.08 | $0.08 | $0.08 |
23 Oct 2024 | $0.08 | $0.00 | 0.00% | 7,657 | $0.08 | $0.08 | $0.08 |
10 Oct 2024 | $0.09 | $0.00 | 0.00% | 117,073 | $0.08 | $0.09 | $0.08 |
09 Oct 2024 | $0.08 | $0.00 | 0.00% | 80,085 | $0.08 | $0.08 | $0.08 |
07 Oct 2024 | $0.08 | $0.00 | 0.00% | 75,208 | $0.08 | $0.08 | $0.08 |
04 Oct 2024 | $0.08 | $0.00 | 0.00% | 2,177 | $0.08 | $0.08 | $0.08 |
03 Oct 2024 | $0.08 | $0.00 | 0.00% | 273,133 | $0.08 | $0.08 | $0.08 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
09 Apr 2024 | Megan Baldwin | Cancelled | 400,000 | $33,600 |
As advised by the company. Cancellation of unlisted options
|
27 Mar 2024 | Thomas (Tom) Duthy | Transfer | 285,661 | $21,424 |
Off-market transfer.
|
27 Mar 2024 | Thomas (Tom) Duthy | Transfer | 285,661 | $21,424 |
Off-market transfer.
|
10 Nov 2023 | Megan Baldwin | Cancelled | 100,000 | $22,500 |
As advised by the company. Cancellation of unlisted options
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David McAuliffe | Non-Executive Director | Mar 2019 |
Mr McAuliffe is a company director and entrepreneur who has had over 24 years of experience, mostly in the international biotechnology field. During that time, he was involved in numerous capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France, and the United Kingdom, many of which have become public companies.
|
Mrs Narelle Warren | Chief Financial OfficerCompany Secretary | Mar 2019 |
Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
|
Mr David Colin Wheeler | Non-Executive Director | Nov 2023 |
Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD). He is currently Non-Executive Chairman of Protean Energy Ltd, PVW Resources Ltd and Avira Resources Ltd and a Non-Executive Director of Ragnar Metals Ltd, Tyranna Resources Ltd, MOAB Ltd, Cycliq Group Ltd, Cradle Resources Ltd and OZZ Resources Ltd.
|
Dr Thomas (Tom) Duthy | Executive Director | Oct 2020 |
Dr Duthy has over 18 years of direct financial market and executive level/Board experience with ASX listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Minderoo Group Pty Ltd | 5,000,000 | 6.65% |
Celtic Capital Pte Ltd <Investment 1 A/C> | 4,450,000 | 5.92% |
Tattarang Pty Ltd <Forrest Fm Inv Peepingee A/C> | 3,846,154 | 5.12% |
Tisia Nominees Pty Ltd <The Henderson Family A/C> | 3,725,000 | 4.96% |
Mr Jason Loveridge | 3,374,462 | 4.49% |
Mr David Jerimiah Mcauliffe <The Lazy D9M Investment A/C> | 3,225,001 | 4.29% |
JK Nominees Pty Ltd <The Jk A/C> | 2,750,000 | 3.66% |
Prof Alexandra Jean Sinclair | 2,500,000 | 3.33% |
Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 2,390,000 | 3.18% |
Mrs Kathryn Mary Salkilld | 2,293,000 | 3.05% |
Bannaby Investments Pty Limited <Bannaby Super Fund A/C> | 1,625,000 | 2.16% |
Porjed Pty Ltd <Deporj A/C> | 1,600,000 | 1.13% |
Rock the Polo Pty Ltd <Rock The Polo A/C> | 1,400,000 | 1.86% |
Oaktone Nominees Pty Ltd <The Grist Investment A/C> | 1,338,518 | 1.78% |
Cityscape Asset Pty Ltd <Cityscape Family A/C> | 1,150,000 | 1.53% |
Cabletime Pty Ltd <Ingodwe A/C> | 1,120,000 | 1.49% |
Hammerhead Holdings Pty Ltd <HHH S/F A/C> | 1,000,000 | 1.33% |
Mr Andrew Clayton <The King Carey A/C> | 1,000,000 | 1.33% |
Mr Anthony De Nicola & Mrs Tanya Louise De Nicola De Nicola Family S/F A/C> | 750,000 | 1.00% |
Endless Summer (Wa) Pty Ltd <Peter Nelson Super Fund A/C> | 750,000 | 1.00% |